Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorothymidine (18F)
- Development stage
- Unknown
- Lead developer
- Synektik
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FLT (18F) Synektik is a radiopharmaceutical diagnostic agent developed by Synektik for positron emission tomography (PET) imaging of malignant tumors. It is a radiolabeled analog of thymidine, specifically 3'-deoxy-3'-[18F]fluorothymidine. The mechanism of action involves its uptake by proliferating cells via the enzyme thymidine kinase 1 (TK1), which is highly expressed during the S-phase of the cell cycle. Unlike thymidine, FLT is not incorporated into DNA but is phosphorylated by TK1 and trapped within the cell, allowing for the visualization and quantification of cellular proliferation. This makes it a valuable tool for assessing tumor aggressiveness and monitoring early response to therapy in various cancers.
- Brand names
- FLT (18F) Synektik
- Other names
- 3'-deoxy-3'-[18F]fluorothymidine[18F]FLTfluorothymidine F-1818F-fluorothymidine
02
Targets
TK2 (Thymidine kinase 2)TK1 (Thymidine kinase 1)ENT1 (Solute carrier family 29 member 1)
Beyond the preview
Go deeper on fluorothymidine (18F).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorothymidine (18F).